(Q38222708)

31 August 2017

title

Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention (English)

1 reference

31 August 2017

1 reference

Atefeh Jafari

1

1 reference

31 August 2017

Hossein Khalili

series ordinal

2

1 reference

31 August 2017

Simin Dashti-Khavidaki

series ordinal

3

1 reference

31 August 2017

publication date

25 June 2014

1 reference

European Journal of Clinical Pharmacology

31 August 2017

published in

1 reference

31 August 2017

volume

70

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

1029-1040

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-014-1712-z

31 August 2017

exact match

0 references

cites work

Tenofovir-induced kidney injury.

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Fanconi syndrome and renal failure induced by tenofovir: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Acute renal failure, Fanconi syndrome and insipidus diabetes in a HIV-infected patient treated with Tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Acute renal failure in an AIDS patient on tenofovir: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Renal safety of tenofovir in HIV treatment-experienced patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Tenofovir-induced acute renal failure in an HIV patient with normal renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Acute tubular necrosis in a patient receiving tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Association of tenofovir exposure with kidney disease risk in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Spectrum of chronic kidney disease in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Tenofovir renal toxicity targets mitochondria of renal proximal tubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Mechanism of active renal tubular efflux of tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Interactions with selected drug renal transporters and transporter-mediated cytotoxicity in antiviral agents from the group of acyclic nucleoside phosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Renal function with use of a tenofovir-containing initial antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Mitochondrial toxicity of antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Drug-induced Fanconi's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Rosiglitazone reverses tenofovir-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Effect of tenofovir, an antiretroviral drug, on hepatic and renal functional indices of Wistar rats: protective role of vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Melatonin protects against gentamicin-induced nephrotoxicity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Selective targeting of an antioxidant to mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Synthesis and characterization of a triphenylphosphonium-conjugated peroxidase mimetic. Insights into the interaction of ebselen with mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

An attempt to prevent senescence: a mitochondrial approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

A mitochondria-targeted macrocyclic Mn(II) superoxide dismutase mimetic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Mitochondria superoxide dismutase mimetic inhibits peroxide-induced oxidative damage and apoptosis: role of mitochondrial superoxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Flavonoid conjugates interact with organic anion transporters (OATs) and attenuate cytotoxicity of adefovir mediated by organic anion transporter 1 (OAT1/SLC22A6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Genistein protects the kidney from cisplatin-induced injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

Potential nephroprotective effects of l-carnitine against drug-induced nephropathy: a review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1712-Z

21 January 2018

1 reference

12 December 2020

Bone scintigraphy and secondary osteomalacia due to nephrotoxicity in a chronic hepatitis B patient treated with tenofovir

1 reference

12 December 2020

The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.

1 reference

12 December 2020

Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure

1 reference

12 December 2020

[Role of bone gammagraphy in the diagnosis of secondary osteomalacia in a patient treated with tenofovir]

1 reference

12 December 2020

Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.

1 reference

12 December 2020

Targeting lipoic acid to mitochondria: synthesis and characterization of a triphenylphosphonium-conjugated alpha-lipoyl derivative

1 reference

12 December 2020

Protective effect of ebselen, a selenoorganic drug, against gentamicin-induced renal damage in rats

1 reference

12 December 2020

Tenofovir-induced nephrotoxicity: myths and facts

1 reference

12 December 2020

Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen

1 reference

12 December 2020

Tubular cell apoptosis and cidofovir-induced acute renal failure.

1 reference

12 December 2020

Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events

1 reference

12 December 2020

Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir

1 reference

12 December 2020

Mitochondrial dysfunction and electron transport chain complex defect in a rat model of tenofovir disoproxil fumarate nephrotoxicity

1 reference

12 December 2020

Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1.

1 reference

12 December 2020

Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy

1 reference

12 December 2020

Preclinical efficacy of melatonin in the amelioration of tenofovir nephrotoxicity by the attenuation of oxidative stress, nitrosative stress, and inflammation in rats

1 reference

12 December 2020

Mitochondria-targeted antioxidants as therapies.

1 reference

12 December 2020

Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons

1 reference

12 December 2020

Do mitochondriotropic antioxidants prevent chlorinative stress-induced mitochondrial and cellular injury?

1 reference

12 December 2020

10.1007/S00228-014-1712-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1024035658

0 references

1 reference